LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "liraglutide" as a keyword



Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis

Sign Up to like & get
recommendations! Published in 2024 at "Obesity Surgery"

DOI: 10.1007/s11695-023-07053-9

Abstract: Purpose Poor response to bariatric surgery, characterized by insufficient weight loss (IWL) or weight regain (WR), poses a significant challenge in obesity treatment. This study aims to assess the effectiveness of liraglutide in addressing this… read more here.

Keywords: surgery; liraglutide; meta analysis; bariatric surgery ... See more keywords

Étude LEADER - liraglutide et événements cardiovasculaires : analyse complémentaire chez les sujets âgés ≥ 75 ans

Sign Up to like & get
recommendations! Published in 2018 at "Annales d'Endocrinologie"

DOI: 10.1016/j.ando.2018.06.203

Abstract: Objectifs Les patients diabetiques âges sont particulierement a risque en raison des comorbidites associes et plus fragiles au regard des effets secondaires des medicaments. Cette analyse post-hoc de l’etude LEADER a ete menee chez des… read more here.

Keywords: leader; liraglutide; leader liraglutide; chez les ... See more keywords

The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy.

Sign Up to like & get
recommendations! Published in 2019 at "Annals of hepatology"

DOI: 10.1016/j.aohep.2019.06.023

Abstract: INTRODUCTION AND OBJECTIVES The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing. Previous studies indicated that Liraglutide, glucagon-like peptide-1 analogue, could regulate glucose homeostasis as a valuable treatment for Type 2 Diabetes. However, the… read more here.

Keywords: lc3 beclin1; liraglutide; hepg2 cells; beclin1 atg7 ... See more keywords

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.

Sign Up to like & get
recommendations! Published in 2019 at "Atherosclerosis"

DOI: 10.1016/j.atherosclerosis.2019.07.007

Abstract: BACKGROUND AND AIMS Atherosclerosis in obesity and type 2 diabetes (T2DM) is associated with low-grade inflammation (LGI) and dyslipidemia, where especially small, dense lipoprotein particles are atherogenic. The glucagon-like peptide-1 receptor agonist, liraglutide, reduces cardiovascular… read more here.

Keywords: newly diagnosed; metformin; statin; coronary artery ... See more keywords

Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.

Sign Up to like & get
recommendations! Published in 2019 at "Metabolism: clinical and experimental"

DOI: 10.1016/j.metabol.2019.03.005

Abstract: BACKGROUND This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who had previously lost weight with liraglutide alone. SUBJECTS/METHODS Participants were 45 adults with obesity (75.6% female, 55.6%… read more here.

Keywords: trial; liraglutide; liraglutide alone; placebo ... See more keywords
Photo from wikipedia

Liraglutide inhibits gallstone formation.

Sign Up to like & get
recommendations! Published in 2021 at "Metabolism: clinical and experimental"

DOI: 10.1016/j.metabol.2021.154728

Abstract: BACKGROUND & AIMS Cholesterol gallstone disease (CGD) is a common gastrointestinal disease. Liraglutide, an analog of glucagon-like peptide 1, has been approved to treat type 2 diabetes. Clinical studies have suggested a potential role of… read more here.

Keywords: fxr; cgd; cholesterol; liraglutide ... See more keywords

Liraglutide alleviates sepsis-induced acute lung injury by regulating pulmonary surfactant through inhibiting autophagy

Sign Up to like & get
recommendations! Published in 2024 at "Immunopharmacology and Immunotoxicology"

DOI: 10.1080/08923973.2024.2384897

Abstract: Abstract Background Pulmonary surfactant (PS) plays an important role in the treatment of sepsis-induced acute lung injury (ALI). Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, improves the secretion and function of PS in ALI, but the… read more here.

Keywords: liraglutide; induced acute; pulmonary surfactant; injury ... See more keywords

Cardiovascular safety of liraglutide for the treatment of type 2 diabetes

Sign Up to like & get
recommendations! Published in 2017 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2017.1313225

Abstract: ABSTRACT Introduction: Liraglutide is a GLP-1 RA that is an option for treatment of T2DM. Typical of all new glucose-lowering agents, its CV safety profile is of great interest. Areas covered: This article outlines the… read more here.

Keywords: treatment; safety; liraglutide; cardiovascular safety ... See more keywords

Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-induced Obesity.

Sign Up to like & get
recommendations! Published in 2023 at "Diabetes"

DOI: 10.2337/db22-0745

Abstract: Inflammation-induced vascular insulin resistance is an early event in diet-induced obesity and contributes to metabolic insulin resistance. To examine whether exercise and glucagon-like peptide 1 (GLP-1) receptor agonism, alone or in combination, modulate vascular and… read more here.

Keywords: inflammation; liraglutide; obesity; metabolic insulin ... See more keywords

1636-P: Liraglutide Mitigates Lipid Accumulation, EMT, and Fibrosis in MASLD via AMPK Activation

Sign Up to like & get
recommendations! Published in 2025 at "Diabetes"

DOI: 10.2337/db25-1636-p

Abstract: Introduction and Objective: Metabolic-associated steatotic liver disease (MASLD) is a prevalent condition associated with obesity and diabetes, frequently progressing to fibrosis and cirrhosis. Effective pharmacological treatments for this condition remain scarce. This study aimed to… read more here.

Keywords: liraglutide; lipid accumulation; fibrosis; emt ... See more keywords

Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway

Sign Up to like & get
recommendations! Published in 2020 at "Frontiers in Cell and Developmental Biology"

DOI: 10.3389/fcell.2020.602574

Abstract: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism has not been fully elucidated. Increasing evidence suggests that autophagy is involved in the… read more here.

Keywords: hepatic steatosis; autophagy lysosomal; treatment; liraglutide ... See more keywords